Segment Information (Tables)

12 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Schedule of Revenues by Product

Product revenues, net consisted of the following:

	2023		2022		2021
	(in millions)
TRIKAFTA/KAFTRIO	$	8,944.7	$	7,686.8	$	5,697.2
KALYDECO	475.5		553.2		684.2
ORKAMBI	326.0		510.7		771.6
SYMDEKO/SYMKEVI	123.0		180.0		420.4
Total product revenues, net	$	9,869.2	$	8,930.7	$	7,573.4

Schedule of Revenues and Property and Equipment by Location

Net product revenues are attributed to countries based on the location of the customer and consisted of the following:

	2023		2022		2021
	(in millions)
United States	$	6,040.4	$	5,699.3	$	5,287.3
Outside of the United States
Europe	3,109.0		2,705.5		1,972.9
Other	719.8		525.9		313.2
Total product revenues outside of the United States	3,828.8		3,231.4		2,286.1
Total product revenues, net	$	9,869.2	$	8,930.7	$	7,573.4

Long-lived assets by location consisted of the following:

	As of December 31,
	2023		2022
	(in millions)
United States	$	1,359.7	$	1,365.5
Outside of the United States
United Kingdom	77.3		75.7
Other	15.9		14.6
Total long-lived assets outside of the United States	93.2		90.3
Total long-lived assets	$	1,452.9	$	1,455.8

Schedule of Significant Customers

Gross product revenues and accounts receivable from each of our customers who individually accounted for 10% or more of total gross product revenues and/or 10% or more of total accounts receivable consisted of the following:

	Percent of Total Gross Product Revenues						Percent of Accounts Receivable
	Year Ended December 31,						As of December 31,
	2023		2022		2021		2023		2022
McKesson Corporation	26	%	25	%	22	%	23	%	22	%
Accredo Health Group, Inc.	11	%	12	%	12	%	<10%		<10%
Walgreen Co.	<10%		10	%	10	%	<10%		<10%
Lloyds Pharmacy*	<10%		<10%		<10%		10	%	12	%
*A wholly owned subsidiary of McKesson Corporation in the U.K. until 2022.